Validation of FLACS against experimental data sets from the model evaluation database for LNG vapor dispersion

The siting of facilities handling liquefied natural gas (LNG), whether for liquefaction, storage or regasification purposes, requires the hazards from potential releases to be evaluated. One of the consequences of an LNG release is the creation of a flammable vapor cloud, that may be pushed beyond the facility boundaries by the wind and thus present a hazard to the public. Therefore, numerical models are required to determine the footprint that may be covered by a flammable vapor cloud as a result of an LNG release. Several new models have been used in recent years for this type of simulations. This prompted the development of the “Model evaluation protocol for LNG vapor dispersion models” (MEP): a procedure aimed at evaluating quantitatively the ability of a model to accurately predict the dispersion of an LNG vapor cloud.This paper summarizes the MEP requirements and presents the results obtained from the application of the MEP to a computational fluid dynamics (CFD) model – FLACS. The entire set of 33 experiments included in the model validation database were simulated using FLACS. The simulation results are reported and compared with the experimental data. A set of statistical performance measures are calculated based on the FLACS simulation results and compared with the acceptability criteria established in the MEP. The results of the evaluation demonstrate that FLACS can be considered a suitable model to accurately simulate the dispersion of vapor from an LNG release.     

Noninvasive prenatal screening for cystic fibrosis using circulating trophoblasts: Detection of the 50 most common disease-causing variants

Objectives

Cystic fibrosis (CF) is one of the most common severe autosomal recessive disorders. Prenatal or preconception CF screening is offered in some countries. A maternal blood sample in early pregnancy can provide circulating trophoblasts and offers a DNA source for genetic analysis of both the mother and the fetus. This study aimed to develop a cell-based noninvasive prenatal test (NIPT) to screen for the 50 most common CF variants.

Methods

Blood samples were collected from 30 pregnancies undergoing invasive diagnostics and circulating trophoblasts were harvested in 27. Cystic fibrosis testing was conducted using two different methods: by fragment length analysis and by our newly developed NGS-based CF analysis.

Results

In all 27 cases, cell-based NIPT provided a result using both methods in agreement with the invasive test result.

Conclusion

This study shows that cell-based NIPT for CF screening provides a reliable result without the need for partner- and proband samples.